Group Art Unit No.: 1624

Amendment to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

1-48 (Cancelled).

49. (Currently amended): A compound of Formula I:

$$(R^3)_k$$
 $(CR^6R^7)_m$
 $(CR^8R^9)_q$
 $(CR^8R^9)_q$

wherein:

X is selected from C_1 - C_8 alkyl, halo, $-OR^{10}$, $-NR^{14}R^{15}$, nitro, cyano, $-COOR^{10}$, $-COR^{13}$, $-OCOR^{13}$, $-N(R^{17})COR^{13}$, $-N(R^{17})CONR^{14}R^{15}$, $-N(R^{17})COOR^{13}$, $-SO_3H$, $-SO_2NR^{14}R^{15}$, $-C(=NR^{17})NR^{14}R^{15}$, $-N(R^{17})SO_2R^{16}$, and a 5 or 6-membered heterocyclic group;

or X and an adjacent R³, taken together with the atoms to which they are bonded, form an alkylenedioxy moiety;

I

Z is CH, CR³ or N, wherein when Z is CH or CR³, k is 0-4 and t is 0 or 1, and when Z is N, k is 0-3 and t is 0;

Y is selected from -O-, -S-, -N(R^{10})-, and -C(R^4)(R^5)-;

 W^1 is selected from [[C_1 - C_6 alkyl,]] C_3 - C_8 cycloalkyl, aryl and Het, wherein said [[C_1 - C_8 alkyl,]] C_3 - C_8 cycloalkyl, aryl and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C_1 - C_6 alkyl, C_3 - C_6 alkenyl, C_3 - C_6 alkynyl, - C_0 - C_6 alkyl- C_0 2 R^{10} , - C_0 - C_6 alkyl-C(0)SR 10 ,

 $-C_0-C_6 \ alkyl-CONR^{11}R^{12}, \ -C_0-C_6 \ alkyl-COR^{13}, \ -C_0-C_6 \ alkyl-NR^{11}R^{12}, \ -C_0-C_6 \ alkyl-SR^{10}, \ -C_0-C_0-C_6 \ alkyl-SR^{10}, \ -C_0-C_0-C_0 \ alkyl-SR^{10}, \ -C_0-C_0-C_0 \ alkyl-SR^{10}, \ -$

 $-C_0-C_6 \text{ alkyl-OR}^{10}, -C_0-C_6 \text{ alkyl-SO}_3H, -C_0-C_6 \text{ alkyl-SO}_2NR^{11}R^{12}, -C_0-C_6 \text{ alkyl-SO}_2R^{10}, -C_0-C_6 \text{ alkyl-SO}_2R^{10},$

-C₀-C₆ alkyl-SOR¹³, -C₀-C₆ alkyl-OCOR¹³, -C₀-C₆ alkyl-OC(O)NR¹¹R¹²,

 $-C_0-C_6 \ alkyl-OC(O)OR^{13}, \ -C_0-C_6 \ alkyl-NR^{11}C(O)OR^{13}, \ -C_0-C_6 \ alkyl-NR^{11}C(O)NR^{11}R^{12}, \ and \ -C_0-C_0 \ alkyl-NR^{11}C(O)NR^{11$

Group Art Unit No.: 1624

-C₀-C₆ alkyl-NR¹¹COR¹³, where said C₁-C₆ alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

W² is selected from H, halo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, $-C_0-C_6 \ alkyl-NR^{11}R^{12}, \ -C_0-C_6 \ alkyl-SR^{10}, \ -C_0-C_6 \ alkyl-OR^{10}, \ -C_0-C_6 \ alkyl-CO_2R^{10}, \ -C_0-C_6$ alkyl-C(O)SR¹⁰, $-C_0-C_6$ alkyl-CONR¹¹R¹², $-C_0-C_6$ alkyl-COR¹³, $-C_0-C_6 \ alkyl-OCOR^{13}, \ -C_0-C_6 \ alkyl-OCONR^{11}R^{12}, \ -C_0-C_6 \ alkyl-NR^{11}CONR^{11}R^{12}, \ -C_0-C_0 \ alkyl-NR^{11}CONR^{11}R^{12}, \$ -C0-C6 alkyl-NR 11 COR 13 , -C0-C6 alkyl-Het, -C0-C6 alkyl-aryl and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl, wherein said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents, and wherein the C3-C7 cycloalkyl, aryl and Het moieties of said -C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-aryl and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-CO₂R¹⁰, $-C_0-C_6 \text{ alkyl-C(O)} SR^{10}, -C_0-C_6 \text{ alkyl-CONR}^{11}R^{12}, -C_0-C_6 \text{ alkyl-COR}^{13}, -C_0-C_6 \text{ alkyl-NR}^{11}R^{12}, -C_0-C_6$ -C₀-C₆ alkyl-SR¹⁰, -C₀-C₆ alkyl-OR¹⁰, -C₀-C₆ alkyl-SO₂NR¹¹R¹², $-C_0-C_6$ alkyl-SO₂R¹⁰, $-C_0-C_6$ alkyl-SOR¹³, $-C_0-C_6$ alkyl-OCOR¹³, $-C_0-C_6 \ alkyl-OC(O)NR^{11}R^{12}, \ -C_0-C_6 \ alkyl-OC(O)OR^{13}, \ -C_0-C_6 \ alkyl-NR^{11}C(O)OR^{13}, \ -C_0-C_0 \ alkyl-NR^{11}C(O)OR^{13}, \ -C_0-C_0 \ alkyl-NR^{11}C(O)OR^{13}, \ -C_0-C_0 \ alkyl-NR^{1$ -C₀-C₆ alkyl-NR¹¹C(O)NR¹¹R¹², and -C₀-C₆ alkyl-NR¹¹COR¹³, where said C₁-C₆ alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

W³ is selected from the group consisting of: H, halo, C₁-C₆ alkyl,

-C₀-C₆ alkyl-NR¹¹R¹², -C₀-C₆ alkyl-SR¹⁰, -C₀-C₆ alkyl-OR¹⁰, -C₀-C₆ alkyl-CO₂R¹⁰,

-C₀-C₆ alkyl-C(O)SR¹⁰, -C₀-C₆ alkyl-CONR¹¹R¹², -C₀-C₆ alkyl-COR¹³,

-C₀-C₆ alkyl-OCOR¹³, -C₀-C₆ alkyl-OCONR¹¹R¹², -C₀-C₆ alkyl-NR¹¹CONR¹¹R¹²,

-C₀-C₆ alkyl-NR¹¹COR¹³, -C₀-C₆ alkyl-Het, -C₁-C₆ alkyl- aryl and

-C₁-C₆ alkyl-C₃-C₇ cycloalkyl, wherein said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

Q is selected from C_3 - C_8 cycloalkyl, Ar and Het; wherein said C_3 - C_8 cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C_1 - C_6 alkyl, C_3 - C_6 alkenyl, C_3 - C_6 alkynyl, $-C_0$ - C_6 alkyl- CO_2R^{10} , $-C_0$ - C_6 alkyl- $C(O)SR^{10}$, $-C_0$ - C_6 alkyl- $CONR^{11}R^{12}$, $-C_0$ - C_6 alkyl- COR^{13} , $-C_0$ - C_6 alkyl- $COR^{11}R^{12}$, $-C_0$ - C_6 alkyl- COR^{10} , $-C_0$ - C_0

Group Art Unit No.: 1624

 $-C_0-C_6$ alkyl-NR¹¹C(O)NR¹¹R¹², and $-C_0-C_6$ alkyl-NR¹¹COR¹³, where said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

p is 0-8;

n is 3;

m is 0 or 1;

q is 0 or 1;

t is 0 or 1;

each R^1 and R^2 are independently selected from H, halo, C_1 - C_6 alkyl, C_3 - C_6 alkenyl, C_3 - C_6 alkyl- $NR^{11}R^{12}$, $-C_0$ - C_6 alkyl- OR^{10} , $-C_0$ - C_6 alkyl- SR^{10} , $-C_1$ - C_6 alkyl-Het, $-C_1$ - C_6 alkyl-Ar and $-C_1$ - C_6 alkyl- C_3 - C_7 cycloalkyl, or R^1 and R^2 together with the carbon to which they are attached form a 3-5 membered carbocyclic or heterocyclic ring, wherein said heterocyclic ring contains one, or more heteroatoms selected from N, O, and S, where any of said C_1 - C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R³ is the same or different and is independently selected from halo, cyano, nitro,

C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het,

-C₀-C₆ alkyl-C₃-C₇ cycloalkyl, -C₀-C₆ alkyl-CO₂R¹⁰, -C₀-C₆ alkyl-C(O)SR¹⁰,

 $-C_0-C_6 \ alkyl-CONR^{11}R^{12}, \ -C_0-C_6 \ alkyl-COR^{13}, \ -C_0-C_6 \ alkyl-NR^{11}R^{12}, \ -C_0-C_6 \ alkyl-SR^{10}, \ -C_0-C_0-C_6 \ alkyl-SR^{10}, \ -C_0-C_0-C_0 \ alkyl-SR^{10}, \ -C_0-$

 $-C_0-C_6 \ alkyl-OR^{10}, \ -C_0-C_6 \ alkyl-SO_3H, \ -C_0-C_6 \ alkyl-SO_2NR^{11}R^{12}, \ -C_0-C_6 \ alkyl-SO_2R^{10}, \$

-C₀-C₆ alkyl-SOR¹³, -C₀-C₆ alkyl-OCOR¹³, -C₀-C₆ alkyl-OC(O)NR¹¹R¹²,

 $-C_0-C_6 \ alkyl-OC(O)OR^{13}, \ -C_0-C_6 \ alkyl-NR^{11}C(O)OR^{13}, \ -C_0-C_6 \ alkyl-NR^{11}C(O)NR^{11}R^{12}, \ and \ -C_0-C_0 \ alkyl-NR^{11}C(O)NR^{11$

-C₀-C₆ alkyl-NR¹¹COR¹³, wherein said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R^4 and R^5 is independently selected from H, halo, C_1 - C_6 alkyl, - C_0 - C_6 alkyl-Het, - C_0 - C_6 alkyl-Ar and - C_0 - C_6 alkyl- C_3 - C_7 cycloalkyl;

R⁶ and R⁷ are each independently selected from H, halo, C₁-C₆ alkyl,

- C_0 - C_6 alkyl-Het, - C_0 - C_6 alkyl-Ar and - C_0 - C_6 alkyl- C_3 - C_7 cycloalkyl;

R⁸ and R⁹ are each independently selected from H, halo, C₁-C₆ alkyl,

- C_0 - C_6 alkyl-Het, - C_0 - C_6 alkyl-Ar and - C_0 - C_6 alkyl- C_3 - C_7 cycloalkyl;

R¹⁰ is selected from H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar,

- C_0 - C_6 alkyl-Het and - C_0 - C_6 alkyl- C_3 - C_7 cycloalkyl;

each R^{11} and each R^{12} are independently selected from H, C_1 - C_6 alkyl, C_3 - C_6 alkenyl, C_3 - C_6 alkyl-Ar, $-C_0$ - C_6 alkyl-Het and $-C_0$ - C_6 alkyl- C_3 - C_7 cycloalkyl, or R^{11}

Group Art Unit No.: 1624

and R¹² together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S;

 R^{13} is selected from C_1 - C_6 alkyl, C_3 - C_6 alkenyl, C_3 - C_6 alkynyl, - C_0 - C_6 alkyl-Ar, - C_0 - C_6 alkyl-Het and - C_0 - C_6 alkyl- C_3 - C_7 cycloalkyl;

-SO₂NH(unsubstituted C_1 - C_6 alkyl) and -SO₂N(unsubstituted C_1 - C_6 alkyl)(unsubstituted

 C_1 - C_6 alkyl);

 R^{16} is C_1 - C_6 alkyl, - C_0 - C_6 alkyl-Ar or - C_0 - C_6 alkyl-Het; and R^{17} is H, C_1 - C_6 alkyl, - C_0 - C_6 alkyl-Ar or - C_0 - C_6 alkyl-Het;

wherein each Ar or aryl independently represent a substituted or unsubstituted carbocyclic aromatic group, which may be optionally fused to another carbocyclic aromatic group moiety or to a cycloalkyl group moiety, wherein said Ar or aryl is optionally substituted by one or more of the substituents independently selected from the group halo, cyano, C₁-C₆ alkyl, C₁-C₆ haloalkyl, -C₀-C₆ alkyl-OH, -C₀-C₆ alkyl-SH, -C₀-C₆ alkyl-NR'R", C₃-C₆ alkenyl, -OC₁-C₆ alkyl, -OC₁-C₆ alkenyl, -C₀-C₆ alkyl-COR', -C₀-C₆ alkyl-CO₂R', -C₀-C₆ alkyl-CONR'R", -OC₀-C₆ alkyl-CO₂H, -OC₂-C₆ alkyl-NR'R",

Group Art Unit No.: 1624

 $-C_0-C_6$ alkyl-C(=NR')NR'R", and $-C_0-C_6$ alkyl- $SO_2NR'R"$, wherein each R' and R" are independently selected from H and unsubstituted C_1-C_6 alkyl,

each Het independently represents a monocyclic 5- to 7-membered, a bicyclic 7- to 10-membered or an 11- to 18-membered tricyclic a tricyclic 11- to 18-membered heterocyclic ring group which is saturated, unsaturated or aromatic, and consists of carbon atoms and from one to three heteroatoms selected from N, O and S, wherein the N or S heteroatoms of said Het are optionally oxidized or the N heteroatom is optionally quaternized, wherein said Het is optionally unsubstituted or substituted by one or more of the substituents independently selected from the group halo, cyano, C₁-C₆ alkyl (which specifically includes C₁-C₆ haloalkyl,

-C₀-C₆ alkyl-OH, -C₀-C₆ alkyl-SH and -C₀-C₆ alkyl-NR'R"), C₃-C₆ alkenyl, oxo,

 $-OC_1-C_6 alkyl, -OC_1-C_6 \ alkenyl, -C_0-C_6 \ alkyl-COR', -C_0-C_6 \ alkyl-CO_2R', -C_0-C_6$

 $-C_0-C_6 \ alkyl-CONR'R", \ -OC_0-C_6 \ alkyl-CO_2H, \ -OC_2-C_6 \ alkyl-NR'R", \ -OC_0-C_0 \ alkyl-$

 $-C_0-C_6 \ alkyl-C(=NR')NR'R" \ and \ -C_0-C_6 \ alkyl-SO_2NR'R", \ wherein \ each \ R' \ are independently selected from H \ and \ unsubstituted \ C_1-C_6 \ alkyl;$

provided that X is not COOR¹⁰ when Y is -O-, p is 0-8, n is 3, m is 1, q is 0 or 1, t is 0, each R^1 and R^2 is independently selected from H, C_1 - C_6 alkyl, -OH, -O- C_1 - C_6 alkyl, -SH, and -S- C_1 - C_6 alkyl, each R^4 , R^5 , R^6 , R^7 , R^8 and R^9 are independently H or C_1 - C_4 alkyl, k is 0 or 1, W^3 is H, W^1 and W^2 are each independently selected from C_3 - C_8 cycloalkyl and aryl and R^3 and Q are as defined above; or

provided that the compound is not

5-[3-[[(3,4-dichlorophenyl)methyl][2-(2-naphthalenyl)ethyl]amino]propoxy]-3-methoxy-1,2-benzenedicarboxylic acid, <u>or</u>

5-[3-[[(3,4-dichlorophenyl)methyl][2-(2-naphthalenyl)ethyl]amino]propoxy]-3-methoxy-1,2-benzenedicarboxylic acid, dimethyl ester [[,]];

4-[[[2 (4-earboxyphenoxy)ethyl][2-[2-[(5-phenylpentyl)oxy]phenyl]ethyl]amino]methyl] benzoic acid,

4 [[[2-[4-(ethoxyearbonyl)phenoxy]ethyl][2-[2-(octyloxy)phenyl]ethyl]amino]methyl]-benzoic acid-methyl ester,

4-[[[2 (4-earboxyphenoxy)ethyl][2-[2-(octyloxy)phenyl]ethyl]amino]methyl], benzoic acid,

& [[[3 (4 fluorophenyl) 1,1 dimethylpropyl](phenylmethyl)amino]methyl] 3 (phenylmethoxy) benzenemethanol hydrochloride;

Group Art Unit No.: 1624

N-[2-(4-amino-3,5-dichlorophenyl)ethyl]-4-fluoro-N (phenylmethyl)-benzenepropanamine monohydrochloride,

N-[2 (4 amino-3,5-dichlorophenyl)ethyl] 4 chloro N (phenylmethyl)-benzenepropanamine monohydrochloride,

4-amino-3,5-dichloro α [[[3 (4-fluorophenyl)propyl](phenylmethyl)amino]methyl]-benzenemethanol-monohydrochloride,

4-amino-3,5-dichloro-α [[[3-(4-chlorophenyl)propyl](phenylmethyl)amino]methyl]-benzenemethanol-monohydrochloride,

2-chloro-5-[2-[[3-(4-fluorophenyl) 1-methylpropyl](phenylmethyl)amino]-1-hydroxyethyl]-benzamide monohydrochloride,

4-[2-[[2-hydroxy 2-[4-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethoxy]-benzeneacetamide,

4 [2 [[2-[3,4-bis(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethoxy]-benzenesulfonamide monohydrochloride,

(R) 3-(phenylmethoxy) α [[[3-[3-

(phenylmethoxy)phenyl]propyl](phenylmethyl)amino]methyl]-benzenemethanol,

2,2-dichloro-acetic acid (R) {benzyl-[3-(3-benzyloxy phenyl) propyl]-amino} (3-benzyloxy phenyl) ethyl ester,

3-amino α-[[[3 (3,4-dimethoxyphenyl)-1-

methylpropyl](phenylmethyl)amino]methyl]-4 (phenylmethoxy)-benzenemethanol,

ex [[[3-(3,4-dimethoxyphenyl) 1-methylpropyl](phenylmethyl)amino]methyl] 3 nitro-4 (phenylmethoxy)-benzenemethanol,

α [[[3 (3,4-dimethoxyphenyl)-1-methylpropyl](phenylmethyl)amino]methyl]-3-nitro-5-(phenylmethoxy) benzenemethanol,

3-amino α [[[3-(3,4-dimethoxyphenyl) 1-

methylpropyl](phenylmethyl)amino]methyl]-5 (phenylmethoxy) benzenemethanol, or

4-[2-[[2-(4-fluorophenoxy)ethyl](phenylmethyl)amino]ethyl]-1-piperazineacetic acid ethyl ester;

or a pharmaceutically acceptable salt or hydrate thereof.

50. (Previously presented): The compound according to claim 49, wherein p is 0, 1 or 2.

Group Art Unit No.: 1624

51. (Previously presented): The compound according to claim 49, wherein t is 0.

- 52. (Previously presented): The compound according to claim 49, wherein R^1 and R^2 are independently H or C_1 - C_4 alkyl or R^1 and R^2 together with the carbon to which they are attached form a 3-5 membered carbocyclic ring.
- 53. (Previously presented): The compound according to claim 49, wherein k is 0 or 1.
- 54. (Previously presented): The compound according to claim 49, wherein \mathbb{R}^3 is selected from halo, \mathbb{C}_1 - \mathbb{C}_4 alkyl and \mathbb{C}_1 - \mathbb{C}_4 alkoxy.
- 55. (Previously presented): The compound according to claim 49, wherein X is selected from C_1 - C_6 alkyl, halo, $-OR^{10}$, $-NR^{14}R^{15}$, cyano, $-COR^{13}$, $-COOR^{10}$, $-OCOR^{13}$, $-N(R^{17})CONR^{14}R^{15}$, $-N(R^{17})COR^{13}$, $-SO_2NR^{14}R^{15}$, $-N(R^{17})SO_2R^{16}$, and a 5 or 6-membered heterocyclic group or X and an adjacent R^3 , taken together with the atoms to which they are bonded, form an alkylenedioxy moiety.
- 56. (Previously presented): The compound according to claim 55, wherein R¹⁰ is H, C₁-C₄ alkyl or phenyl; R¹³ is H, C₁-C₄ alkyl, -C₀-C₄ alkyl-C₃-C₇ cycloalkyl, or -C₀-C₄ alkyl-phenyl; R¹⁴ and R¹⁵ are each independently selected from H, C₁-C₆ alkyl, -C₀-C₄ alkyl-Ar, -C₀-C₄ alkyl-Het, -C₀-C₄ alkyl-C₃-C₇ cycloalkyl, -C₀-C₄ alkyl-O-Ar, -C₀-C₄ alkyl-O-Het, -C₀-C₄ alkyl-O-C₃-C₇ cycloalkyl, -C₀-C₄ alkyl-S(O)₂-C₁-C₄ alkyl, -C₀-C₄ alkyl-S(O)₂-Ar, -C₀-C₄ alkyl-S(O)₂-Het, -C₀-C₄ alkyl-S(O)₂-C₃-C₇ cycloalkyl, -C₀-C₄ alkyl-NH-Ar, -C₀-C₄ alkyl-NH-Het, -C₀-C₄ alkyl-NH-C₃-C₇ cycloalkyl, -C₀-C₄ alkyl-N(C₁-C₄ alkyl)-Ar, -C₀-C₄ alkyl-N(C₁-C₄ alkyl)-Het, -C₀-C₄ alkyl-N(C₁-C₄ alkyl)-C₃-C₇ cycloalkyl, -C₀-C₄ alkyl-Ar, -C₀-C₄ alkyl-Het and -C₀-C₄ alkyl-C₃-C₇ cycloalkyl, or R¹⁴ and R¹⁵, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S, wherein said C₁-C₆ alkyl is optionally substituted by one or more of the substituents independently selected from the group halo,

Group Art Unit No.: 1624

-OH, -SH, -NH₂, -NH(unsubstituted C_1 - C_4 alkyl), -N(unsubstituted C_1 - C_4 alkyl)(unsubstituted C_1 - C_4 alkyl), unsubstituted -OC₁- C_4 alkyl, -CO₂H, -CO₂(unsubstituted C_1 - C_4 alkyl), -CONH(unsubstituted C_1 - C_4 alkyl), -CON(unsubstituted C_1 - C_4 alkyl)(unsubstituted C_1 - C_4 alkyl), -SO₃H, -SO₂NH₂, -SO₂NH(unsubstituted C_1 - C_4 alkyl) and -SO₂N(unsubstituted C_1 - C_4 alkyl)(unsubstituted C_1 - C_4 alkyl)(unsubstituted C_1 - C_4 alkyl) or phenyl; and C_1 - C_4 alkyl).

57. (Previously presented): The compound according to claim 49 wherein each R⁴ and R⁵ are independently selected from H and C₁-C₃ alkyl.

Claim 58 (Cancelled).

- 59. (Previously presented): The compound according to claim 49, wherein R⁸ and R⁹ are each H.
- 60. (Previously presented): The compound according to claim 49, wherein Q is a substituted or unsubstituted phenyl or furanyl group or a benzo[1,3]dioxyl or benzo[1,4]dioxyl group containing one, two or three substituents selected from halo, C₁-C₄ alkyl; C₁-C₄ alkylthio; or -NR^{Q1}R^{Q2}, where R^{Q1} and R^{Q2} taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may optionally contain one or more additional heteroatoms selected form N, O and S.
- 61. (Previously presented): The compound according to claim 60, wherein said substituents are selected from fluoro, chloro, trifluoromethyl, tert-butyl, isopropyl, methylthio and piperidin-1-yl.
- 62. (Previously presented): The compound according to claim 49, wherein m is 0 or m is 1 and R^6 and R^7 are each H.
- 63. (Previously presented): The compound according to claim 49, wherein W¹ is phenyl, naphthyl, thienyl, pyridyl, furanyl, pyrrolyl, cyclohexyl, cyclopentyl, morpholinyl, or pyrrolidinyl, where each phenyl, naphthyl, thienyl, pyridyl, furanyl, pyrrolyl, cyclohexyl,

Group Art Unit No.: 1624

cyclopentyl, morpholinyl, or pyrrolidinyl may be optionally substituted from 1 to 3 times with one or more of the substituents independently selected from C₁-C₄ alkyl, -OH, halo, -O-C₁-C₄ alkyl, and -C₁-C₄ haloalkyl.

- 64. (Previously presented): The compound according to claim 49, wherein W^2 is C_1 - C_4 alkyl, C_2 - C_4 alkynyl, C_3 - C_6 cycloalkyl, aryl, Het hydroxy, aryloxy-, C_1 - C_4 alkoxy-, $-OCOC_1$ - C_4 alkyl, -OCOaryl, or $-NR^{W1}R^{W2}$, where R^{W1} and R^{W2} are independently H or C_1 - C_4 alkyl or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may optionally contain one or more additional heteroatoms selected form N, O and S.
- 65. (Withdrawn): The compound according to claim 49, wherein W^3 is H or C_1 - C_4 alkyl.
- 66. (Currently amended): The compound according to claim 49, wherein X is selected from C₁-C₆ alkyl, halo, -OR¹⁰, -NR¹⁴R¹⁵, cyano, -COR¹³, -COOR¹⁰, -OCOR¹³, $-N(R^{17})CONR^{14}R^{15}$, $-N(R^{17})COR^{13}$, $-SO_2NR^{14}R^{15}$, $-N(R^{17})SO_2R^{16}$, and a 5 or 6-membered heterocyclic group or X and an adjacent R³, taken together with the atoms to which they are bonded, form an alkylenedioxy moiety, where R¹⁰ is H, C₁-C₄ alkyl or phenyl, R¹³ is H, C_1 - C_4 alkyl, $-C_0$ - C_4 alkyl- C_3 - C_7 cycloalkyl, or $-C_0$ - C_4 alkyl-phenyl, R^{14} and R^{15} are each independently selected from H, C₁-C₆ alkyl, -C₀-C₄ alkyl-Ar, -C₀-C₄ alkyl-Het, -C₀-C₄ alkyl-C₃-C₇ cycloalkyl, -C₀-C₄ alkyl-O-Ar, -C₀-C₄ alkyl-O-Het, $-C_0-C_4$ alkyl $-O-C_3-C_7$ cycloalkyl, $-C_0-C_4$ alkyl $-S(O)_2-C_1-C_4$ alkyl, $-C_0-C_4$ alkyl $-S(O)_2-Ar$, $-C_0-C_4$ alkyl-S(O)₂-Het, $-C_0-C_4$ alkyl-S(O)₂-C₃-C₇ cycloalkyl, $-C_0-C_4$ alkyl-NH-Ar, -C₀-C₄ alkyl-NH-Het, -C₀-C₄ alkyl-NH-C₃-C₇ cycloalkyl, -C₀-C₄ alkyl-N(C₁-C₄ alkyl)-Ar, $-C_0-C_4$ alkyl-N(C₁-C₄ alkyl)-Het, $-C_0-C_4$ alkyl-N(C₁-C₄ alkyl)-C₃-C₇ cycloalkyl, -C₀-C₄ alkyl-Ar, -C₀-C₄ alkyl-Het and -C₀-C₄ alkyl-C₃-C₇ cycloalkyl, or R¹⁴ and R¹⁵, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S, wherein said C₁-C₆ alkyl is optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, -NH₂, -NH(unsubstituted C₁-C₄ alkyl), -N(unsubstituted C₁-C₄ alkyl)(unsubstituted C₁-C₄ alkyl), unsubstituted -OC₁-C₄ alkyl,

Group Art Unit No.: 1624

-CO₂H, -CO₂(unsubstituted C₁-C₄ alkyl), -CONH₂, -CONH(unsubstituted C₁-C₄ alkyl), -CON(unsubstituted C₁-C₄ alkyl)(unsubstituted C₁-C₄ alkyl), -SO₃H, -SO₂NH₂, $-SO_2NH (unsubstituted\ C_1-C_4\ alkyl)\ and\ -SO_2N (unsubstituted\ C_1-C_4\ alkyl) (unsubstituted\ C_1-C_4\ alkyl)$ C_1 - C_4 alkyl), R^{16} is C_1 - C_4 alkyl or phenyl, and R^{17} is H or C_1 - C_4 alkyl; p is 0, 1 or 2; R^1 and R² are independently H or C₁-C₄ alkyl or R¹ and R² together with the carbon to which they are attached form a 3-5 membered carbocyclic ring; k is 0 or k is 1 and R3 is halo, C1-C4 alkyl or C₁-C₄ alkoxy; n is 3 and each R⁴ and R⁵ are independently selected from H and C₁-C₃ alkyl; Z is CH or N; Y is -O- or -C(R⁴)(R⁵)-; q is 1; R⁸ and R⁹ are each H; Q is a substituted or unsubstituted phenyl or furanyl group or a benzo[1,3]dioxyl or benzo[1,4]dioxyl group, where the substituted phenyl or furanyl group contains one, two or three substituents selected from halo, C_1 - C_4 alkyl; C_1 - C_4 alkylthio; or -NR^{Q1}R^{Q2}, where R^{Q1} and R^{Q2} taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may optionally contain one or more additional heteroatoms selected form N, O and S; t is 0 or 1; m is 0 or 1; R⁶ and R⁷ are independently selected from H and C₁-C₄ alkyl; W¹ is [[methyl,]] unsubstituted phenyl, naphthyl, pyridyl, thienyl or pyrrolyl or substituted phenyl or pyridyl containing one or two substituents independently selected from halo, alkyl and alkoxy, specifically, chloro, methyl and methoxy; W2 is C1-C4 alkyl, C2-C4 alkynyl, C3-C6 cycloalkyl, aryl, Het hydroxy, aryloxy-, C1-C4 alkoxy-, -OCOC1-C4 alkyl, -OCOaryl, or -NRW1RW2, where RW1 and RW2 are independently H or C1-C4 alkyl or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may optionally contain one or more additional heteroatoms selected form N, O and S; W3 is H or C1-C4 alkyl; or a pharmaceutically acceptable salt or [[solvate]] hydrate thereof.

Group Art Unit No.: 1624

```
-(S)-NHCH(CH<sub>3</sub>)CO<sub>2</sub>H, -NHCH<sub>2</sub>-1H-imidazol-2-yl, -NHCH<sub>2</sub>-(1-CH<sub>3</sub>-imidazol-2-yl,
-NH-(pyrimidin-2-yl), -morpholin-4-yl, -thiomorpholin-4-yl, -piperidin-1-yl,
-piperidin-1-yl-(4-carboxylic acid), -piperidin-1-yl-(4-acetic acid), -piperidin-4-yl-(1-acetic
acid), -2,5-dimethyl-pyrrol-1-yl, -pyrrolidin-1-yl, -((R)-2-CO<sub>2</sub>H-pyrrolidin-1-yl),
-((S)-2-CO<sub>2</sub>H-pyrrolidin-1-yl), -piperazin-1-yl, -(4-methyl-piperazin-1-yl),
-piperazin-1-yl-(4-acetic acid), -NHCH2-(5-bromo-thien-2-yl), -NHCH2-1H-imidazol-2-yl,
-NHCH<sub>2</sub>-(1-methyl-imidazol-2-yl, -NHCOCH<sub>3</sub>, -N(CH<sub>3</sub>)COCH<sub>3</sub>, -NHCO<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>,
-NHCOCH<sub>2</sub>CH<sub>3</sub>, -NHCOC(CH<sub>3</sub>)<sub>2</sub>, -NHCO-furan-2-yl, -N(CH<sub>3</sub>)CO-furan-2-yl,
-NHCO-thien-2-yl, -NHCO-cyclopropyl, -NHCO-(5-bromo-thien-2-yl,
-NHCO-(2,5-dimethyl-pyrrol-3-yl), -NHSO<sub>2</sub>CH<sub>3</sub>, -N(CH<sub>3</sub>)SO<sub>2</sub>CH<sub>3</sub>, -NHSO<sub>2</sub>CF<sub>3</sub>,
-NHSO<sub>2</sub>phenyl, -N(CH<sub>3</sub>)SO<sub>2</sub>phenyl, -NHSO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -NHSO<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>,
-NHSO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -NHSO<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,-NHCONH(2-chlorophenyl),
-N(CH<sub>3</sub>)CONH(3,5-dimethoxyphenyl), -N(CH<sub>3</sub>)CONH(2-chlorophenyl),
-N(CH<sub>3</sub>)CO-(benzo[1,3]diox-5-yl), -SO<sub>2</sub>NHCH<sub>3</sub>, and -SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>; p is 0, 1 or 2; R^1 and R^2
are HC1-C4 alkyl or R1 and R2 together with the carbon to which they are attached form a 3, 4
or 5 membered carbocyclic ring; Z is CH or N; k is 0 or k is 1 and R³ is methyl,
trifluoromethyl, chloro or methoxy; n is 3 and R<sup>4</sup> and R<sup>5</sup> are independently selected from H
and methyl; Y is -O- or -C(R<sup>4</sup>)(R<sup>5</sup>)-; q is 1; R<sup>8</sup> and R<sup>9</sup> are each H; Q is
2-chloro-3-(trifluoromethyl)phenyl, 3-methyl-4-fluoro-phenyl, 4-tert-butyl-phenyl,
4-(methylthio)phenyl, 2,4,5-trifluoro-phenyl, 4-isopropyl-phenyl,
5-(piperidin-1-yl)-furan-2-yl, benzo[1,3]diox-5-yl, or 2,3-dihydrobenzo[1,4]dioxin-6-yl; t is
0 or 1; m is 0 or 1; R<sup>6</sup> and R<sup>7</sup> are independently selected from H and methyl; W<sup>1</sup> is
[[methyl,]] phenyl, naphth-1-yl, pyrid-2-yl, 4-methyl-pyrid-2-yl, thien-2-yl, thien-3-yl,
pyrrol-2-yl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methoxyphenyl, or
4-methoxyphenyl; W<sup>2</sup> is methyl, ethyl, ethynyl, isopropyl, n-butyl, 2-methylpropyl,
trifluorormethyl, cyclohexyl, unsubstituted phenyl, hydroxy, methoxy, phenoxy,
dimethylamino, morpholin-4-yl, phenylcarbonyloxy, or methylcarbonyloxy; W3 is H or
methyl; or a pharmaceutically acceptable salt or [[solvate]] hydrate thereof.
```

Claims 68-69 (Cancelled).

Group Art Unit No.: 1624

70. (Withdrawn): The compound according to claim 49, wherein W^1 and W^2 are not each independently C_3 - C_8 cycloalkyl or aryl or W^3 is not H or any one of R^6 or R^7 is not H or R^8 and R^9 are each C_1 - C_4 alkyl when:

X is COOR¹⁰;

Z is CH or CR³ and k is 0-4 or Z is N and k is 0-3;

p is 0-8;

n is 3;

q is 0 or 1;

Q is selected from optionally unsubstituted or substituted C₃-C₈ cycloalkyl, phenyl and monocyclic Het;

each R^1 and R^2 is independently selected from H, C_1 - C_6 alkyl, -OH, -O- C_1 - C_6 alkyl, -SH, and -S- C_1 - C_6 alkyl; and

each R^3 is the same or different and is independently selected from halo, cyano, nitro, $-\text{CONR}^{12}R^{13}$, $-\text{COR}^{14}$, $-\text{SR}^{11}$, $-\text{SO}_2R^{11}$, $-\text{SO}_2R^{14}$, $-\text{OCOR}^{14}$ and optionally unsubstituted or substituted C_1 - C_6 alkyl, C_3 - C_6 alkenyl, -5-6 membered-Het, $-C_0$ - C_6 alkyl- $-\text{CO}_2R^{11}$, or $-C_0$ - $-C_6$ alkyl- $-\text{NR}^{12}R^{13}$.

71. (Previously presented): A pharmaceutical composition comprising the compound according to claim 49 and a pharmaceutically acceptable carrier or diluent.

Claims 72-91 (Cancelled).

- 92. (Withdrawn): A method for the prevention or treatment of an LXR mediated disease or condition, wherein said disease or condition is selected from atherosclerosis and inflammation, comprising administering a therapeutically effective amount of the compound according to claim 49.
- 93. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 52.

Group Art Unit No.: 1624

94. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 55.

- 95. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 56.
- 96. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 57.
- 97. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 60.
- 98. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 63.
- 99. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 64.
- 100. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 66.
- 101. (Withdrawn): The method according to claim 92, comprising administering a therapeutically effective amount of the compound according to claim 67.
- 102. (Currently amended, Withdrawn): The method according to claim 92, comprising administering a compound selected from:
- 2-(3-[3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-dephenylethyl)amino]propoxy}phenyl)-ethanol;
- 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}phenyl)-ethanol,

(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-{3-[3-(1,2,4-triazol-3-ylmethyl)-phenoxy]-propyl}-amine,

Group Art Unit No.: 1624

- (2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]-propyl}-amine,
- (S)-(2-chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)- $\{3$ -[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxy]-propyl $\}$ -amine,
- (R)-(2-chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxy]-propyl}-amine,
- (S)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy}-phenyl)acetic acid,
- (R)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy}-phenyl)acetic acid,
- 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-acetoxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid,
- (3-{3-[(2-acetoxy-2-phenyl-ethyl)-(2-chloro-3-trifluoromethyl-benzyl)-amino]-propoxy}-phenyl)-acetic acid methyl ester,
- (3-{4-[(2-chloro-3-(trifluoromethyl)benzyl)-(2,2-diphenylethyl)-amino]butyl}phenyl)-acetic acid,
- 1-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-cyclobutanecarboxylic acid,
- N-(2,2-diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-[2-hydroxy-2-methylpropyl]phenoxy)propylamine,
- $(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-\{2-[(1H-imidazol-2-ylmethyl)-amino]-ethyl\}-phenoxy)-propyl]-amine,\\$
- N-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-methanesulfonamide,
- N-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-N-methyl-amine,
- [2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethylamino]-acetic acid,
- (R)-1-[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethyl]-pyrrolidine-2-carboxylic acid,
- furan-2-carboxylic acid N-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-amide,

Group Art Unit No.: 1624

N-(2-[3-chlorophenyl]-propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy) propylamine,

(2-chloro-3-trifluoromethyl-benzyl)-{3-[3-(2-morpholin-4-yl-ethyl)-phenoxy}-propyl}-((S)-2-phenyl-propyl amine,

[4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,

2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-2-methyl-propionic acid,

(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-piperazin-1-yl)-phenoxy]-propyl}-amine,

 $(3-\{(R)-3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-butoxy\}-phenyl)-acetic acid,$

[1-(3-{3-[(2-chloro-3-(trifluoromethyl)-benzyl)-(2,2-diphenylethyl)-amino]-propoxy}-phenyl-piperidine-4-carboxylic acid,

[4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,

[4-(3-{(R)-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-methyl-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,

and a pharmaceutically acceptable salt or hydrate thereof.

- 103. (Withdrawn): A method for increasing reverse cholesterol transport, said method comprising administering a therapeutically effective amount of the compound according to claim 49.
- 104. (Withdrawn): A method for inhibiting cholesterol absorption, said method comprising administering a therapeutically effective amount of the compound according to claim 49.
 - 105. (Currently amended): A compound selected from:
- 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-dephenylethyl)amino]propoxy}phenyl) ethanol 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}phenyl)-ethanol; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzylethyl)amino]propoxy}phenylethyl

Group Art Unit No.: 1624

Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}-phenyl)acetic acid, Noxide; (3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}bromobenzene; (4-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2diphenylethyl)amino]propoxy}-bromobenzene; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2diphenylethyl)-{3-[3-(1,2,4-triazol-3-ylmethyl)-phenoxyl-propyl}-amine; (2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]propyl}-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2-cyclohexyl-2-phenyl-ethyl)-{3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxyl-propyl}-amine; (S)-(2-Chloro-3-trifluoromethylbenzyl)-(2-phenyl-propyl)- $\{3-[3-(1,2,3,4-\text{tetrazol-}3-\text{ylmethyl})-\text{phenoxy}]$ -propyl $\}$ -amine; (R)-(2-Chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)phenoxy]-propyl}-amine; (S)-2-(3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-phenylpropyl)amino]propoxy}-phenyl)acetic acid; (R)-2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy}-phenyl)acetic acid; 2 (3 {3 {{2-} Chloro-3-(trifluoromethyl)benzyl] naphthalen-1-ylmethyl-amino]propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]-benzylamino]propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)-benzyl]phenethylamino]propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-hydroxy-2-phenylethyl)amino]propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2acetoxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenoxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid; Benzoic acid 2-[3-(3-carboxymethyl-phenoxy){2-chloro-3-(trifluoromethyl)benzyl}propylamino]-1-phenyl ethyl ester; (3-{3-[(2-Acetoxy-2-phenylethyl)-(2-chloro-3-trifluoromethyl-benzyl)-amino]-propoxy}-phenyl)-acetic acid methyl ester; Benzoic acid 2-[3-(3-methoxycarbonylmethyl-phenoxy){2-chloro-3-(trifluoromethyl)benzyl}propylamino]-1-phenyl ethyl ester; (3-{4-[(2-Chloro-3-(trifluoromethyl)benzyl)-(2,2-diphenylethyl)-amino]butyl}phenyl)-acetic acid; (3-{3-[(4-Fluoro-3-methyl-benzyl)-((R)-2-phenyl-propyl)-amino]-propoxyl-phenyl)-acetic acid; (3-{3-[Benzo[1,3]dioxol-5-ylmethyl-((R)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-acetic acid; (3-{3-[(4-tert-Butyl-benzyl)-((R)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-acetic acid; (3-{3-[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-((R)-2-phenyl-propyl)-amino]-propoxy}phenyl)-acetic acid; (3-{3-[(4-Methylsulfanyl-benzyl)-((R)-2-phenyl-propyl)-amino]propoxy}-phenyl)-acetic acid; (3-{3-[((R)-2-Phenyl-propyl)-(2,4,5-trifluoro-benzyl)-amino]-

Group Art Unit No.: 1624

propoxy}-phenyl)-acetic acid; (3-{3-{((R)-2-Phenyl-propyl)-(5-piperidin-1-yl-furan-2ylmethyl)-amino]-propoxy}-phenyl)-acetic acid; (3-{3-[(4-Isopropyl-benzyl)-((R)-2-phenylpropyl)-amino]-propoxy}-phenyl)-acetic acid; 2-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)diphenylethyl-amino]-propoxy}-phenyl)-propane-1,3-diol; N-(3-{3-[(2-Chloro-3trifluoromethyl-benzyl)-2,2-diphenylethyl-aminol-propoxyl-phenyl)-carbamic acid tert-butyl ester; 3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethylamino]-propoxy}phenylamine; N-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]propoxy}-phenyl)-acetamide; Furan-2-carboxylic acid N-(3-{3-[(2-Chloro-3-trifluoromethylbenzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-amide; N-(3-{3-[(2-Chloro-3trifluoromethyl-benzyl)-2,2-diphenylethyl-aminol-propoxy}-phenyl)-methanesulfonamide; N-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)benzenesulfonamide; 1-(2-Chloro-phenyl)-3-(3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2diphenylethyl-amino]-propoxy}-phenyl)-urea; N-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-N-methyl-amine; N-(3-{3-[(2-Chloro-3trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-N-methyl-acetamide; Furan-2-carboxylic acid N-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethylamino]-propoxy}-phenyl)-N-methyl-amide; N-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-N-methyl-methanesulfonamide; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-N-methylbenzenesulfonamide; 3-(2-Chloro-phenyl)-1-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2diphenylethyl-amino]-propoxy}-phenyl)-1-methyl-urea; Benzo[1,3]dioxole-5-carboxylic acid N-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-Nmethyl-amide; 1-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]propoxy}-phenyl)-3-(3,5-dimethoxy-phenyl)-1-methyl-urea; Propane-1-sulfonic acid (5-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-2-methyl-phenyl)amide; 3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-2-methylphenylamine; 2-Chloro-5-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]propoxy}-phenylamine; 3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)amino]-propoxy}-phenyl)-cyclopentyl-amine; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-isopropyl-amine; Chloro-3-trifluoromethylbenzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-ethyl-amine; (3-{3-[(2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-(3-methyl-butyl)-

Group Art Unit No.: 1624

amine; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)isobutyl-amine; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]propoxy}-phenyl)-(2,2,2-trifluoroethyl)-amine; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-cyclopropylmethy-l-amine; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-(2-ethyl-butyl)amine; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}phenyl)-(2,2-dimethyl-propyl)-amine; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2diphenyl-ethyl)-amino]-propoxy}-phenyl)-hexyl-amine; Butyl-(3-{3-[(2-chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-amine; [1-(3-{3-[(2-Chloro-3-(trifluoromethyl)-benzyl)-(2,2-diphenylethyl)-amino]-propoxy}-phenyl-piperidine-4-carboxylic acid; [1-(3-{3-[(2-Chloro-3-(trifluoromethyl)-benzyl)-(2,2-diphenylethyl)amino]-propoxy}-phenyl-piperidine-4-yl-acetic acid; [4-(3-{3-[(2-Chloro-3-(trifluoromethyl)benzyl)-(2,2-diphenylethyl-amino]-propoxy}-phenyl)-piperidin-1-yl]-acetic acid; rac-±-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(trifluoro-phenyl-propyl)-amino]-propoxy}-phenyl)acetic acid; rac-±-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2-dimethylamino-2-phenylethyl)-amino]-propoxy}-phenyl)-acetic acid; rac-±-(3-{3-[(2-Chloro-3-trifluoromethylbenzyl)-(2-morpholin-4-yl-2-phenyl-ethyl)-amino]-propoxy}-phenyl)-acetic acid; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(6-morpholin-4-yl-pyridin-2-yloxy)propyl]-amine; [3-(6-Chloro-pyridin-2-yloxy)-propyl]-(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[6-(4-methyl-piperazin-1-yl)-pyridin-2-yloxy]-propyl}-amine; (2-Chloro-3-trifluoromethylbenzyl)-(2,2-diphenyl-ethyl)-[3-(6-piperazin-1-yl-pyridin-2-yloxy)-propyl]-amine; [4-(6-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)- amino]-propoxy}-pyridin-2-yl)piperazin-1-yl]-acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]((S)-2-phenylpropyl)amino]- (R)-1-methyl-propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]((S)-2-phenyl-propyl)amino]-(R)-1-methyl-propoxy}-phenyl) ethanol; 2-(3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl]((S)-2-phenyl-propyl)amino]-(R)-2methyl-propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]((S)-2phenyl-propyl)amino]-(R)-2-methyl-propoxy}-phenyl) ethanol; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]((R)-2-phenyl-propyl)amino]-(R)-2-methyl-propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]((R)-2-phenyl-propyl)amino]-(R)-2methyl-propoxy}-phenyl)ethanol; (R)-2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-

Group Art Unit No.: 1624

diphenylethyl)amino]-2-methyl-propoxy}-phenyl)ethanol; 3-{3-[(3-Chloro-2-trifluoromethylbenzyl)-diphenylethyl-amino]-propoxy-N,N-dimethyl-benzenesulfonamide: Cyclopropanecarboxylic acid 3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethylamino]-propoxy}-benzylamide; N -(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethylamino]-propoxy}-benzyl)-isobutyramide; Acetic acid (3-{3-[(2-chloro-3-trifluoromethylbenzyl)-diphenylethyl-amino]-propoxy}-benzylcarbamoyl)-methyl ester; N- -(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-benzyl)-propionamide; 2,5-Dimethyl-2-H -pyrazole-3-carboxylic acid 3-{3-[(2-chloro-3-trifluoromethyl-benzyl)diphenylethyl-amino]-propoxy}-benzylamide; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2diphenyl-ethyl)-(3-o-tolyloxy-propyl)-amine; 2-{3-[(2-Chloro-3-trifluoromethyl-benzyl)diphenylethyl-amino]-propoxy}-benzonitrile; 3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)diphenylethyl-amino]-propoxy}-benzonitrile; [3-(3-Chloro-phenoxy)-propyl]-(2-chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(2-methoxy-phenoxy)-propyl]-amine; [3-(2-Chloro-phenoxy)-propyl]-(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethylbenzyl)-(2,2-diphenyl-ethyl)-(3-phenoxy-propyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-isopropyl-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethylbenzyl)-(2,2-diphenyl-ethyl)-[3-(4-methoxy-phenoxy)-propyl]-amine; 3-{3-[(Chlorotrifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenol; 2-{3-[(Chlorotrifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenol; 3-{3-[(Chlorotrifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenylamine; (2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-trifluoromethyl-phenoxy)-propyl]-amine; 1-(3-{3-[(Chloro-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethanone; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-phenylamine; [3-(Benzo[1,3]dioxol-5-yloxy)-propyl]-(2-chloro-3-trifluoromethyl-benzyl)-(2,2diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-(3-mtolyloxy-propyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3methoxy-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-isobutyl-phenoxy)-propyl]-amine; [3-(3-Butyl-phenoxy)-propyl]-(2-chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-{3-[3-(2,2-dimethyl-propyl)-phenoxy]-propyl}-(2,2-diphenyl-ethyl)-amine; (4-{3-[(2-Chloro-3trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-benzyl)-methyl-amine; (2-Chloro-3-

Group Art Unit No.: 1624

trifluoromethyl-benzyl)-[3-(4-dimethylaminomethyl-phenoxy)-propyl]-(2,2-diphenyl-ethyl)amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(4-morpholin-4-ylmethylphenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[4-(4methyl-piperazin-1-ylmethyl)-phenoxy]-propyl}-amine; (3-{3-[(Chloro-trifluoromethylbenzyl)-diphenylethyl-amino]-propoxy}-benzyl)-methyl-amine; (2-Chloro-3-trifluoromethylbenzyl)-[3-(3-dimethylaminomethyl-phenoxy)-propyl]-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-morpholin-4-ylmethyl-phenoxy)propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl)-benzyl]-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl)-benzyl]-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl)-benzyl]-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl)-benzyl]-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl)-benzyl]-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl)-benzyl]-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl)-benzyl]-(2,2-diphenyl-ethyl)-(2,2piperazin-1-ylmethyl)-phenoxy]-propyl}-amine; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)diphenylethyl-amino]-propoxy}-benzyl)-isopropyl-amine; {3-[(2-Chloro-3-trifluoromethylbenzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-trifluoromethyl-phenylamine; {3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-methylphenylamine; Ethanesulfonic acid (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl-amino)]-propoxy}-4-methyl-phenyl)-amide; Propane-2-sulfonic acid (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-methyl-phenyl)-amide; Methanesulfonic acid (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethylamino)]-propoxy}-4-methyl-phenyl)-amide; 2,2,2-Trifluoro-ethanesulfonic acid (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-methyl-phenyl)amide; Ethanesulfonic acid (3-{3-{(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethylamino)]-propoxy}-phenyl)-amide; 2,2,2-Trifluoro-ethanesulfonic acid (3-{3-[(2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-phenyl)-amide; N-(3-{3-{(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-phenyl)-1,1,1trifluoro-methanesulfonamide; Propane-2-sulfonic acid (3-{3-[(2-Chloro-3-trifluoromethylbenzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-phenyl)-amide; {3-[(2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-methoxy-phenylamine; Ethanesulfonic acid (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]propoxy}-4-methoxy-phenyl)-amide; (2-Chloro-3-trifluoromethyl-benzyl)-{3-[3-(2morpholin-4-yl-ethyl)-phenoxy]-propyl}-((S)-2-phenyl-propyl amine; (2-Chloro-3trifluoromethyl-benzyl)-{3-[3-(2-ethylamino-ethyl)-phenoxy]-propyl}-((S)-2-phenyl-propyl)amine; (3-{(R)-3-[(2-Chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]butoxy}-phenyl)-acetic acid; (3-{(S)-3-[(2-Chloro-3-trifluoromethyl-benzyl)-((S)-2-phenylpropyl)-amino]-butoxy}-phenyl)-acetic acid; 2-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-

Group Art Unit No.: 1624

((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-ethanol; 2-(3-{3-[(2-Chloro-3trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-2-methyl-propionic acid; 2-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-((R)-2-phenyl-propyl)-amino]-propoxy}phenyl)-2-methyl-propionic acid; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2-thiophen-3yl-propyl)-amino]-propoxy}-phenyl)-acetic acid; 2-(3-{3-[(2-Chloro-3-trifluoromethylbenzyl)-(2-thiophen-3-yl-propyl)-amino]-propoxy}-phenyl)-ethanol; (3-{3-[(2-Chloro-3trifluoromethyl-benzyl)-(2-thiophen-2-yl-propyl)-amino]-propoxy}-phenyl)-acetic acid; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2-pyridin-2-yl-propyl)-amino]-propoxy}-phenyl)acetic acid; [3-(3-{(2-Chloro-3-trifluoromethyl-benzyl)-[2-(4-methyl-pyridin-2-yl)-propyl]amino}-propoxy)-phenyl]-acetic acid; [3-(3-{(2-Chloro-3-trifluoromethyl-benzyl)-[3,3,3trifluoro-2-(1H -pyrrol-2-yl)-propyl]-amino}-propoxy) -phenyl]-acetic acid; (2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-(3-{3-[2-(4-methyl-piperazin-1-yl)-ethyl]phenoxy}-propyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(2methylamino-ethyl)-phenoxyl-propyl}-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2.2diphenyl-ethyl)-[3-(3-{2-[(1H-imidazol-2-ylmethyl)-amino] -ethyl}-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(2-ethylamino-ethyl)phenoxy]-propyl}-amine; [3-(3-{2-[(5-Bromo-thiophen-2-ylmethyl)-amino]-ethyl}-phenoxy)propyl]-(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-{2-[(thiophen-2-ylmethyl)-amino]-ethyl}phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-{3-[3-(2-dimethylaminoethyl)-phenoxy]-propyl}-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(2-pyrrolidin-1-yl-ethyl)-phenoxyl-propyl}-amine; (2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(2-morpholin-4-yl-ethyl)-phenoxy] propyl}-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{(R)-1-methyl-3-[3-(2-morpholin-4-yl-ethyl) -phenoxy]-propyl}-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2diphenyl-ethyl)-{(R)-2-methyl-3-[3-(2-morpholin-4-yl-ethyl) -phenoxy]-propyl}-amine; {3-[3-(2-Amino-ethyl)-phenoxy]-propyl}-(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-amine; [2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}phenyl)-ethyl]-isopropyl-amine; [2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethylamino]-propoxy}-phenyl)-ethyl]-propyl-amine; 2-[2-(3-{3-[(2-chloro-3-trifluoromethylbenzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethylamino]-ethanol; (2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-{2-[(1-methyl-1H-imidazol-2-ylmethyl)-

Group Art Unit No.: 1624

amino]-ethyl}-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-{3-[3-(2-thiomorpholin-4-yl-ethyl)-phenoxy] -propyl}-amine; [2-(3-{3-[(2-chloro-3trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethylamino]-acetic acid; [2-(3-{(R)-3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-butoxy}-phenyl)ethylamino]-acetic acid; {[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethylamino]-propoxy}-phenyl)-ethyl]-methyl-amino}-acetic acid; 2-[2-(3-{3-[(2-chloro-3trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethylamino]-2-methylpropionic acid; (S)-2-[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]propoxy}-phenyl)-ethylamino]-propionic acid; (R)-1-[2-(3-{3-[(2-chloro-3-trifluoromethylbenzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethyl]-pyrrolidine-2-carboxylic acid; (S)-1-[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethyl]pyrrolidine-2-carboxylic acid; [2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethylamino]-propoxy}-phenyl)-ethyl]-pyrimidin-2-yl-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-morpholin-4-yl-phenoxy)-propyl]-amine; (2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-piperidin-1-yl-phenoxy)-propyl]-amine; (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-diethylamine; (2-Chloro-3-trifluoromethyl-benzyl)-{3-[3-(2,5-dimethyl-pyrrol-1-yl)-phenoxy]propyl \}-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-[3-(3-piperazin-1-yl-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-[3-(3-piperazin-1-yl-phenoxy)-propyl]-amine; (2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[(R)-2-methyl-3-(3-piperazin-1-yl-phenoxy)propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-isobutyl-[3-(3-piperazin-1-yl-phenoxy)propyl] amine; [4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]propoxy}-phenyl)-piperazin-1-yl]-acetic acid; [4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid; [4-(3-{(R)-[(2chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-methyl-propoxy}-phenyl)-piperazin-1-yl]-acetic acid; [4-(3-[3-[(2-chloro-3-trifluoromethyl-benzyl) isobutyl-amino] propoxy] phenyl)-piperazin-1-yl]-acetic acid; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-piperazin-1-yl)-phenoxy]-propyl}-amine; (2-Chloro-3-trifluoromethylbenzyl)-(2,2-diphenyl-ethyl)-[3-(3-pyrrolidin-1-yl-phenoxy)-propyl]-amine; (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenylamino)-acetic acid; [(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-N-methyl-

Group Art Unit No.: 1624

amino]-acetic acid; N-(2,2-Diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-[3-(2methyl-2-aminopropyl)phenoxy]propylamine; N-(2,2-Diphenylethyl)-N-(2-chloro-3trifluoromethylbenzyl)-3-(3-[2-hydroxymethyl]phenoxy)propylamine; N-(2,2-Diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-[2-hydroxy-2-methylpropyl]phenoxy)propylamine; N-(2,2-Diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-Nmethylsulfonamidophenoxy)propylamine; N-(2-[2-Chlorophenyl]-propyl)-N-(2-chloro-3trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; N-(2-[3-Chlorophenyl]propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; N-(2-[4-Chlorophenyl]-propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3carboxymethylenephenoxy)propylamine; N-(2-[2-Methoxyphenyl]-propyl)-N-(2-chloro-3trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; N-(2-[4-Methoxyphenyl]-propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3carboxymethylenephenoxy)propylamine; N-(2-Phenyl-4-methylpentyl)-N-(2-chloro-3trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; N-(2-Phenylbutyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; N-(2-[2-Methyl-2-phenyl]propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3carboxymethylenephenoxy)propylamine; N-(2-Phenyl-3-methylbutyl)-N-(2-chloro-3trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; N-(2-Phenylhexyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; N-(2-Phenyl-3-butynyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3carboxymethylenephenoxy)propylamine; (S)-N-(2-Phenyl-2-methoxyethyl)-N-(2-chloro-3trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; (R)-N-(2-Phenyl-2-methoxyethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3carboxymethylenephenoxy)propylamine; (R)-N-(2-Phenyl-2-methoxyethyl)-N-(2-chloro-3trifluoromethylbenzyl)-3-(3-[2-hydroxy-2-methylpropyl]phenoxy)propylamine; 2-(3-[3-[2-hydroxy-2-methylpropyl]phenoxy)propylamine; Chloro-3 (trifluoromethyl)benzyl](2 methyl-propyl)amino] propoxy)-phenyl)acetic acid; 1-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)cyclobutanecarboxylic acid; 1-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethylamino]-propoxy}-phenyl)-cyclopentanecarboxylic acid; 1-(3-{3-[(2-Chloro-3trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)cyclopropanecarboxylic acid;

and a pharmaceutically acceptable salt or hydrate thereof.

Group Art Unit No.: 1624

106. (Currently amended, Withdrawn): The compound according to claim 49, selected from:

2-(3-[3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-

dephenylethyl)amino]propoxy]phenyl) ethanol

2-(3-[3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-

diphenylethyl)aminolpropoxy}phenyl)-ethanol,

(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-{3-[3-(1,2,4-triazol-3-ylmethyl)-phenoxy]-propyl}-amine,

 $(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]-propyl}-amine,$

(2-chloro-3-trifluoromethyl-benzyl)-(2-cyclohexyl-2-phenyl-ethyl)-{3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]-propyl}-amine,

 $2\hbox{-}(3\hbox{-}\{3\hbox{-}[[2\hbox{-}chloro-3\hbox{-}(trifluoromethyl)benzyl]-benzylamino] propoxy}-phenyl) acetic acid,$

2-(3-{3-[[2-chloro-3-(trifluoromethyl)-benzyl]phenethylamino]propoxy}-phenyl)acetic acid,

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-hydroxy-2-phenyl-ethyl)amino]propoxy}-phényl)acetic acid,

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-acetoxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid,

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenoxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid,

(3-{3-[(2-acetoxy-2-phenyl-ethyl)-(2-chloro-3-trifluoromethyl-benzyl)-amino]-propoxy}-phenyl)-acetic acid methyl ester,

benzoic acid 2-[3-(3-methoxycarbonylmethyl-phenoxy){2-chloro-3-(trifluoromethyl)benzyl}propylamino]-1-phenyl ethyl ester,

(3-{4-[(2-chloro-3-(trifluoromethyl)benzyl)-(2,2-diphenylethyl)-amino]butyl}phenyl)-acetic acid,

2 (3-[3-[[2-chlore 3-(trifluoromethyl)benzyl](2,2-dephenylethyl)amino]propoxy]phenyl) ethanol,

(2-chloro 3-trifluoromethyl-benzyl) (2,2-diphenylethyl) [3 [3 (1,2,4-triazol-3-ylmethyl) phenoxy] propyl] amine,

Group Art Unit No.: 1624

(2-chloro 3-trifluoromethyl-benzyl) (2,2-diphenyl-ethyl) {3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxy] propyl}-amine,

furan-2-carboxylic acid N-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-amide,

2-(3-{3-[{2-chlore-3-(trifluoromethyl)benzyl](2-acetoxy-2-phenyl-ethyl)amine)propoxy}-phenyl)acetic acid,

(3-{3-{(2-acetoxy-2-phenyl ethyl)-(2-chloro-3-trifluoromethyl-benzyl) amino}-propoxy}-phenyl) acetic acid methyl ester,

(3-{4-{(2-chloro-3 (trifluoromethyl)benzyl) (2,2-diphenylethyl) amino}butyl}phenyl)-acetic acid.

1-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-cyclobutanecarboxylic acid,

N-(2,2-diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-[2-hydroxy-2-methylpropyl] phenoxy) propylamine,

(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-{2-[(1H-imidazol-2-ylmethyl)-amino] -ethyl}-phenoxy)-propyl]-amine,

N-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-methanesulfonamide,

N-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-N-methyl-amine,

[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethylamino]-acetic acid,

N-(2-[3-chlorophenyl]-propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine,

[4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,

 $(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-\{3-[3-(4-methyl-piperazin-1-yl)-phenoxy]-propyl\}-amine,\\$

[1-(3-{3-[(2-chloro-3-(trifluoromethyl)-benzyl)-(2,2-diphenylethyl)-amino]-propoxy}-phenyl-piperidine-4-carboxylic acid,

and a pharmaceutically acceptable salt or hydrate thereof.

Group Art Unit No.: 1624

- 107. (Withdrawn): The compound according to claim 49, selected from:
- $(S)-(2-chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-\{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxy]-propyl\}-amine,$
- $(R)-(2-chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-\{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxy]-propyl\}-amine,$
- (S)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy}-phenyl)acetic acid,
- (R)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy}-phenyl)acetic acid,
- (R)-1-[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethyl]-pyrrolidine-2-carboxylic acid,
- $\label{eq:chloro-3-trifluoromethyl-benzyl} $$ -{3-[3-(2-morpholin-4-yl-ethyl)-phenoxy]-propyl}-((S)-2-phenyl-propyl amine,$
- $2-(3-\{3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy\}-phenyl)-2-methyl-propionic acid,$
- $(3-\{(R)-3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-butoxy\}-phenyl)-acetic acid,$
- [4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,
- [4-(3-{(R)-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-methyl-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,

and a pharmaceutically acceptable salt or hydrate thereof.